Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2010
03/18/2010US20100068177 Methods of organ regeneration
03/18/2010CA2736922A1 Use of an ang-(1-7) receptor agonist in acute lung injury
03/18/2010CA2736623A1 Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs
03/18/2010CA2736421A1 Combination therapy for the treatment of diabetes and related conditions
03/18/2010CA2731660A1 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
03/17/2010EP2163260A2 Chimpanzee adenovirus vaccine carriers
03/17/2010EP2163258A1 Preventive/remedy for cancer
03/17/2010EP2163256A1 Specific binding proteins and uses thereof
03/17/2010EP2163252A1 Composition containing licorice-derived polyphenol
03/17/2010EP2163241A1 Pharmaceutical compositions for the coordinated delivery of NSAIDs
03/17/2010EP2162141A1 Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue
03/17/2010EP2162130A1 Triazol compounds for treating biofilm formation
03/17/2010EP2162125A2 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
03/17/2010EP1455847B1 Feminine care products for the delivery of therapeutic substances
03/17/2010EP1385870B1 Peptides as ns3-serine protease inhibitors of hepatitis c virus
03/17/2010EP1315502B1 Method for treating erectile dysfunction and increasing libido in men
03/17/2010EP1303536B1 Novel fibroblast growth factor (fgf23) and methods for use
03/17/2010CN101674849A N-halogenated amino acid formulations
03/17/2010CN101674848A N-halogenated amino acid formulations and methods for cleaning and disinfection
03/17/2010CN101674827A Benzimidazole derivatives and methods of use thereof
03/17/2010CN101674810A Targeting agent for cancer cell or cancer-associated fibroblast
03/17/2010CN101674808A Polyaphron topical composition with vitamin d and corticosteroid
03/17/2010CN101671393A Angiopoietin-2 specific binding agents
03/17/2010CN101670116A Forebody drug with conjugate linoleic acid connected with antitumor drug and preparation method thereof
03/17/2010CN101670112A Stable albumins lipid medicine carrying system and preparation method thereof
03/17/2010CN101670108A Medicine carrying system based on nano graphene oxide
03/17/2010CN101670106A Natural activator of soluble guanylate cyclase
03/17/2010CN101670101A Attenuated live vaccine
03/17/2010CN101669958A Pharmaceutical uses of bisphosphonates
03/17/2010CN101669941A Method for treating malignant tumors with joint medicament administration and anti-malignant tumor medicament
03/17/2010CN101669925A Dry powder inhalation, preparation method and application thereof
03/17/2010CN101669899A Sustained-release implant taking maize protein as main framework material or matrix and use thereof
03/16/2010US7678822 inhibiting rejection of a transplanted organ, tissue or cell in a recipient mammal; immunosuppressive agent; autoimmune diseases
03/16/2010US7678810 activin receptor-like kinase 5 (ALK5) (which is a TGF- beta type I receptor) inhibitor ; glomerulonephritis, diabetic nephropathy, hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, or alopeciarosis; hair growth stimulant
03/16/2010US7678809 Useful in the treatment of chronic and acute pain; 1-[4-dibenzocycloheptyl-4-piperidinyl]-1,3-dihydro-2H-1,3-benzamidazol-2-one;
03/16/2010US7678805 inhibitors are unable to promote death of IL-3 dependent cells cultured in presence of IL-3; non-toxic, selective and potent
03/16/2010US7678798 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV
03/16/2010US7678759 Diagnosis and treatment of neuroectodermal tumors
03/16/2010US7678552 Method for selecting therapeutic agents for cancer treatment
03/16/2010US7678391 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
03/16/2010US7678372 Tyrosine kinase inhibitors; anticancer agents; genetic engineered protein
03/16/2010US7678366 for high penetration into fingernails and toenails; contains humectant for trapping water and liquid nail lacquer containing film forming agent
03/16/2010CA2639525A1 Topical composition for the protection and/or treatment of radiation related skin damages
03/16/2010CA2436724C Use of inhibitors of dipeptidyl peptidase iv (dp iv) in combination with inhibitors of alanyl-aminopeptidase (apn)
03/16/2010CA2432006C Pharmaceutical preparation with retarding active ingredient release, method for its production and its use
03/16/2010CA2395121C Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
03/16/2010CA2358420C New compounds for the treatment of cancer
03/16/2010CA2314286C Anthelmintic compositions
03/16/2010CA2302838C Modulation of the sphingosine kinase signalling pathway
03/16/2010CA2296766C Aggrecan degrading metallo proteases
03/16/2010CA2200054C Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
03/16/2010CA2191577C Method for treating and preventing atherosclerosis
03/16/2010CA2160693C Oral drug delivery compositions and methods
03/11/2010WO2010028067A1 Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
03/11/2010WO2010028055A1 Insulin with a basal release profile
03/11/2010WO2010027428A1 Platinum ( iv) complexes for use in dual mode pharmaceutical therapy
03/11/2010WO2010027264A1 Hangover relief by compositions comprising oral rehydration solution
03/11/2010WO2010027005A1 Substituted amine derivative and medicinal composition comprising same as the active ingredient
03/11/2010WO2010026966A1 Novel anti-hcv agent and use thereof
03/11/2010WO2010026965A1 Cell capable of replicating novel hcv replicon, cell capable of replicating full-length hcv rna, and use of those cells
03/11/2010WO2010026766A1 Agent for treating myelofibrosis
03/11/2010WO2010026760A1 Compositions wherein bioactive components are stably sealed
03/11/2010WO2010026652A2 Safe tooth extraction method and method of cleaning and sterilizing oral organs using neutralization reaction between sterilized water and aqueous antioxidant solution
03/11/2010WO2010026602A2 Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis
03/11/2010WO2010026596A2 Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses
03/11/2010WO2010026526A1 Combination therapy for tuberculosis
03/11/2010WO2010026375A1 Pharmaceutical preparation comprising a catechin
03/11/2010WO2010026129A1 The trpvl antagonist sb-705498 for treating rhinitis
03/11/2010WO2010026128A1 N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis
03/11/2010WO2010025934A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid
03/11/2010WO2010001186A4 Combination of a parp inhibitor and an akt kinase activating compound
03/11/2010WO2009152415A3 Reducing myocardial reperfusion injury by the combination therapy of protein kinase a activation and b1-adrenergic receptor blockade
03/11/2010WO2009141738A3 Modified drugs for use in liposomal nanoparticles
03/11/2010WO2009090453A3 Compositions comprising (r) -verapamil having mt1 receptor activity
03/11/2010US20100063094 Methods for treatment of colorectal cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
03/11/2010US20100063060 Therapeutic agent for glaucoma comprising Rho Kinhase inhibitor and prostaglandin
03/11/2010US20100063012 Compositions and methods for the treatment of inflammatory diseases
03/11/2010US20100062972 Triazole compounds and uses related thereto
03/11/2010US20100062443 Using myeloblastosis oncogene expression profile as tool in detection of cell proliferative disorders associated with respiratory system
03/11/2010US20100062055 Lipid-based nitric oxide donors
03/11/2010US20100062041 Skin sunstitutes, preparation methods and uses thereof
03/11/2010US20100062016 Microorganisms for therapy
03/11/2010US20100062010 Novel peptide compound
03/11/2010US20100062003 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
03/11/2010US20100061985 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
03/11/2010US20100061965 Respiratory syncytial virus renders dendritic cells tolerogenic
03/11/2010US20100061963 Methods of Improving Stem Cell Homing and Engraftment
03/11/2010CA2735709A1 Agent for treating myelofibrosis
03/11/2010CA2735139A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid
03/10/2010EP2161286A1 Antibodies
03/10/2010EP2161258A2 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
03/10/2010EP1554586B1 Identification of drugs against mycobacteria
03/10/2010EP1423376B1 Bicyclic compound, production and use thereof
03/10/2010EP1377293B1 Aryl and biaryl piperidines used as mch antagonists
03/10/2010CN101668543A Tgf-beta stimulant and further agent to reduce side effects
03/10/2010CN101668542A Agent for treatment of pulmonary disease
03/10/2010CN101664555A Combined medicinal composition for treating infectious diseases of urogenital system
03/10/2010CN101664554A Combination product comprising SRC kinase inhibitor AZD0530 and an antioestrogen or EGFR-TK-inhibitor
03/10/2010CN101664553A Stabilization of hypoxia inducible factor (HIF) alpha
03/10/2010CN101664552A Stabilization of hypoxia inducible factor (HIF) alpha
1 ... 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 ... 1151